The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy.
The new combination immunotherapy + chemotherapy regimens represent a major change in systemic therapy for patients with metastatic NSCLC. Case managers and other health care providers have less experience with these new immunotherapy + chemotherapy regimens or the newer targeted therapies that have different mechanisms of action and side effects than traditional cytotoxic chemotherapy regimens.
Recommendations and requirements for biomarker testing vary by the type of immune checkpoint inhibitor (ICI), specific tumor characteristics, and treatment setting.
Immunotherapy recommendations for patients with non-small cell lung cancer (NSCLC) are rapidly changing, and health care providers need to be aware of the most current recommendations in the NCCN Guidelines to improve outcomes for their patients.
The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for SCLC regarding immunotherapy, systemic therapy, and radiation therapy.
Join Sally Barbour, PharmD, BCOP, CPP, FHOPA, from Duke Cancer Institute for this webinar in the 2018 NCCN Pharmacy Update Series on the topic The Evolving Landscape of Immunotherapy and Targeted Therapy for Non-Small Cell Lung Cancer.
The goal of this activity is to improve participants’ knowledge of and competence in applying immune checkpoint inhibitors in the treatment of patients with stage III NSCLC.
Join Sally Barbour, PharmD, BCOP, CPP, FHOPA, from Duke Cancer Institute for this webinar in the 2018 NCCN Pharmacy Update Series on the topic The Evolving Landscape of Immunotherapy and Targeted Therapy for Non-Small Cell Lung Cancer.
Facebook
X
LinkedIn
Forward
